Skip to main content
    R

    Rigel Pharmaceuticals Inc (RIGL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $43.73
    -0.73 (-1.64%)

    Market Cap: $837.18M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Rigel Pharmaceuticals Inc (RIGL) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Rigel Pharmaceuticals reported revenue of $294.28M for the fiscal year ended Dec 31, 2025, up 64.1% from the year before. That year, net income was $367.02M with a net margin of 124.7%, operating cash flow was $75.66M and free cash flow was $75.66M. The quarter ended Sep 30, 2026 had revenue of $80.89M and net income of $13.19M.

    Revenue and Margins

    The operating margin was 42.6% in the fiscal year ended Dec 2025, the highest of the 6 years shown with an operating margin. Over the 9 years to Dec 2025, revenue grew from $20.38M, a compound annual rate of 34.5%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$294.28M+64.1%93.3%42.6%124.7%
    Dec 2024$179.28M+53.4%89.6%13.5%9.8%
    Dec 2023$116.88M-2.8%93.9%-17.5%-21.5%
    Dec 2022$120.24M-19.4%98.5%-46.2%-48.7%
    Dec 2021$149.24M+37.4%99.3%-8.4%-12.0%
    Dec 2020$108.62M+83.2%99.2%-26.7%-27.4%
    Dec 2019$59.29M+33.2%98.5%-116.5%-112.8%
    Dec 2018$44.51M+892.6%99.4%-163.3%-158.3%
    Dec 2017$4.48M-78.0%100.0%-1775.6%-1755.7%
    Dec 2016$20.38MN/A100.0%-342.2%-340.0%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income rose 1999.7% from the year before. In the quarter ended Sep 2026, net income fell 52.7% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$294.28M$179.28M$116.88M$120.24M$149.24M$108.62M$59.29M$44.51M$4.48M$20.38M
    Cost of revenue$19.62M$18.65M$7.11M$1.75M$1.08M$895.00K$906.00K$287.00K$0$0
    Gross profit$274.66M$160.63M$109.77M$118.49M$148.15M$107.73M$58.38M$44.22M$4.48M$20.38M
    Research and development$33.30M$23.38M$24.52M$60.27M$65.24M$60.10M$52.88M$46.90M$46.27M$63.45M
    Operating income$125.47M$24.19M-$20.49M-$55.55M-$12.50M-$28.97M-$69.09M-$72.68M-$79.62M-$69.74M
    Net income$367.02M$17.48M-$25.09M-$58.57M-$17.91M-$29.74M-$66.89M-$70.48M-$78.72M-$69.30M
    EBITDA$126.73M$25.71M-$19.73M-$54.62M-$11.05M-$28.39MN/AN/A-$79.50M-$68.69M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$80.89M$78.70M$58.82M$69.80M$69.46M$101.69M$53.33M$57.60M$55.31M$36.84M$29.53M$35.79M
    Gross profit$70.11M$70.18M$54.21M$63.85M$64.71M$97.18M$48.92M$51.81M$47.28M$34.03M$27.51M$32.00M
    Operating income$17.11M$23.57M$11.88M$23.17M$28.42M$61.10M$12.77M$16.66M$14.06M$447.00K-$6.97M$1.97M
    Net income$13.19M$17.29M$8.65M$268.06M$27.90M$59.61M$11.45M$14.34M$12.42M-$1.03M-$8.25M$737.00K
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $52.29M exceeded cash and equivalents by $11.71M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$513.59M$163.98M$117.22M$134.28M$167.33M$110.38M$147.57M$139.11M$119.11M$78.13M
    Current assets$240.17M$135.10M$99.27M$115.90M$154.47M$88.98M$119.00M$136.99M$117.43M$76.21M
    Cash and equivalents$40.58M$56.75M$32.79M$24.46M$18.89M$30.37M$22.52M$76.32M$38.29M$17.63M
    Total liabilities$122.11M$160.69M$145.87M$147.90M$136.95M$76.35M$93.75M$29.23M$18.46M$23.11M
    Short-term debt$29.81M$7.27M$7.23M$0$9.89M$8.62M$7.27MN/A$284.00K$3.22M
    Long-term debt$22.48M$52.41M$52.37M$39.45M$19.91M$19.82M$9.81MN/A$0$0
    Shareholder equity$391.48M$3.29M-$28.64M-$13.62M$30.37M$34.03M$53.81M$109.88M$100.65M$55.03M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$523.88M$521.07M$504.61M$513.59M$242.53M$206.74M$175.97M$163.98M$139.42M$128.41M$126.52M$117.22M
    Total liabilities$78.77M$95.64M$104.71M$122.11M$124.92M$124.80M$157.41M$160.69M$154.06M$158.32M$158.19M$145.87M
    Cash and equivalents$46.65M$60.82M$24.41M$40.58M$48.53M$53.41M$45.73M$56.75M$51.69M$36.05M$25.57M$32.79M
    Shareholder equity$445.11M$425.42M$399.90M$391.48M$117.61M$81.93M$18.57M$3.29M-$14.64M-$29.91M-$31.67M-$28.64M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 100.0% of operating cash flow.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$75.66M$31.47M-$5.74M-$73.76M$5.88M-$52.19M-$41.51M-$58.83M-$77.56M-$75.89M
    Capital expenditures$0$36.00K$0$450.00K$627.00K$1.26M$1.46M$1.11M$164.00K$804.00K
    Free cash flow$75.66M$31.43M-$5.74M-$74.21M$5.25M-$53.45M-$42.97M-$59.93M-$77.72M-$76.69M
    Investing cash flow-$92.36M$4.13M-$4.30M$72.78M-$80.04M$47.47M-$23.66M$24.96M-$19.47M$24.88M
    Financing cash flow$601.00K-$11.64M$18.37M$6.55M$62.67M$12.57M$11.37M$71.89M$117.69M$25.18M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$34.56M$30.65M$2.73M$21.98M$24.03M$30.54M-$893.00K$14.50M$21.68M$302.00K-$5.01M-$6.24M
    Capital expendituresN/AN/A$0$12.00K$12.00K$0$0$26.00K$10.00K$222.00K$138.00K$110.00K
    Free cash flowN/AN/A$2.73M$21.97M$24.02M$30.54M-$893.00K$14.48M$21.67M$80.00K-$5.15M-$6.35M
    Last 12 quarters

    Frequently Asked Questions About RIGL

    What is Rigel Pharmaceuticals' annual revenue?

    Rigel Pharmaceuticals reported revenue of $294.28M for the fiscal year ended Dec 31, 2025.

    How fast is Rigel Pharmaceuticals' revenue growing?

    Revenue was up 64.1% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 34.8%.

    Is Rigel Pharmaceuticals profitable?

    Yes. Rigel Pharmaceuticals reported net income of $367.02M for the fiscal year ended Dec 31, 2025, with a net margin of 124.7%.

    How much free cash flow does RIGL generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $75.66M minus capital expenditures of $0 produced free cash flow of $75.66M.

    How much debt does Rigel Pharmaceuticals have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $22.48M, short-term debt of $29.81M and cash and equivalents of $40.58M.